Machine signal
Active cluster sell — 3 distinct insiders, $343K, window ends Sep 9, 2026.
Figures computed from official regulatory filings — .
Analysttarget 9 USD (+153%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 15.99% · institutions 76.88% · short 7.8% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for AN2 Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
38 buys103 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Marks Gilbert Lynn | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aziz Kabeer | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martin Patricia A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trenor Cameron C. III | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trenor Cameron C. III | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Readnour Robin Shanetrack record | Sell | $3.5K | SEC |
| Readnour Robin Shanetrack record | Sell | $3.2K | SEC |
| Readnour Robin Shanetrack record | Sell | $19.6K | SEC |
| Readnour Robin Shanetrack record | Sell | $31.9K | SEC |
| Readnour Robin Shanetrack record | Sell | $28.4K | SEC |
| Readnour Robin Shanetrack record | Sell | $17.5K | SEC |
| Williams Sarah Joanne | Sell | $1.5K | SEC |
| FitzPatrick Margaret M | Buy | $11.6K | conv 51First in 12mo | SEC |
| Readnour Robin Shanetrack record | Sell | $112.4K | Unusual size | SEC |
| Readnour Robin Shanetrack record | Sell | $100.3K | Unusual size | SEC |
| Zakrzewski Joseph Strack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marks Gilbert Lynn | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martin Patricia A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Eizen Joshua M | Sell | $24.8K | Unusual size | SEC |
| Aziz Kabeer | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams Sarah Joanne | Sell | $1.2K | SEC |
| Aziz Kabeer | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martin Patricia A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marks Gilbert Lynn | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Eizen Joshua M | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |